Assessing immune responses to pneumococcal vaccines

Abstract
The recent article and letter1,2 discussing recommendations for use of heptavalent pneumococcal conjugate vaccine (Prevenar) for at risk children is timely and interesting. We concur with the authors that further immunogenicity studies are necessary in various high risk groups to demonstrate the best protective schedule. Children older than 2 years with recurrent infections and normal humoral immunity assessed by serum immunoglobulin levels and specific antibody responses to protein antigens, but repeated …

This publication has 2 references indexed in Scilit: